Abstract
Alzheimers disease (AD) is an incurable age-related neurodegenerative disorder characterized by profound memory dysfunction. This bellwether symptom suggests involvement of the hippocampus -- a brain region responsible for memory formation -- and coincidentally an area heavily burdened by hyperphosphorylated tau and neuritic plaques of amyloid beta (Aβ). Recent evidence suggests that pre-fibrillar soluble Aβ underlies an early, progressive loss of synapses that is a hallmark of AD. One of the downstream effects of soluble Aβ aggregates is the activation of the phosphatase calcineurin (CaN). This review details the evidence of CaN hyperactivity in ‘normal’ aging, models of AD, and actual disease pathogenesis; elaborates on how this could manifest as memory impairment, neuroinflammation, hyperphosphorylated tau, and neuronal death.
Keywords: Alzheimers, amyloid beta, calcineurin, calcium, pre-fibrillar soluble A, glycogen synthase kinase-3 beta (GSK-3 ), voltage-gated sodium (Na+), neurotransmitter, Ca2+ fluctuation
Current Neuropharmacology
Title: A Role for Calcineurin in Alzheimers Disease
Volume: 9 Issue: 4
Author(s): Lindsay C. Reese and Giulio Taglialatela
Affiliation:
Keywords: Alzheimers, amyloid beta, calcineurin, calcium, pre-fibrillar soluble A, glycogen synthase kinase-3 beta (GSK-3 ), voltage-gated sodium (Na+), neurotransmitter, Ca2+ fluctuation
Abstract: Alzheimers disease (AD) is an incurable age-related neurodegenerative disorder characterized by profound memory dysfunction. This bellwether symptom suggests involvement of the hippocampus -- a brain region responsible for memory formation -- and coincidentally an area heavily burdened by hyperphosphorylated tau and neuritic plaques of amyloid beta (Aβ). Recent evidence suggests that pre-fibrillar soluble Aβ underlies an early, progressive loss of synapses that is a hallmark of AD. One of the downstream effects of soluble Aβ aggregates is the activation of the phosphatase calcineurin (CaN). This review details the evidence of CaN hyperactivity in ‘normal’ aging, models of AD, and actual disease pathogenesis; elaborates on how this could manifest as memory impairment, neuroinflammation, hyperphosphorylated tau, and neuronal death.
Export Options
About this article
Cite this article as:
C. Reese Lindsay and Taglialatela Giulio, A Role for Calcineurin in Alzheimers Disease, Current Neuropharmacology 2011; 9 (4) . https://dx.doi.org/10.2174/157015911798376316
DOI https://dx.doi.org/10.2174/157015911798376316 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Click Test: A Novel Tool to Quantify the Age-Related Decline of Fast Motor Sequencing of the Thumb
Current Aging Science Meet Our Editorial Board Member:
Protein & Peptide Letters Protein Oxidative Folding in the Intermembrane Mitochondrial Space: More than Protein Trafficking
Current Protein & Peptide Science Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences EDITOR’S PERSPECTIVE [The Challenges for Drug Development: Cytokines, Genes, and Stem Cells]
Current Neurovascular Research Role of Nuclear Factor Kappa B (NF-κB) Signalling in Neurodegenerative Diseases: An Mechanistic Approach
Current Neuropharmacology Development of New Drugs that Act Through Membrane Receptors and Involve an Action of Inverse Agonism
Recent Patents on CNS Drug Discovery (Discontinued) Editorial [ Neurodegenerative Disorders: From Molecules to Man (Part 2) Guest Editors: Giuseppe Di Giovanni, Vincenzo Di Matteo and Ennio Esposito ]
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) The Infectious Etiology of Alzheimer’s Disease
Current Neuropharmacology P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets Adult Neurogenesis in the Hypothalamus: Evidence, Functions and Implications
CNS & Neurological Disorders - Drug Targets Hydroxamate, a Key Pharmacophore Exhibiting a Wide Range of Biological Activities
Mini-Reviews in Medicinal Chemistry Current Research on Opioid Receptor Function
Current Drug Targets Posttranslational Modifications of Tau - Role in Human Tauopathies and Modeling in Transgenic Animals
Current Drug Targets Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
CNS & Neurological Disorders - Drug Targets Ischemic Neuronal Damage
Current Pharmaceutical Design Recent Advances in Neuroinflammation Therapeutics: PPARs/LXR as Neuroinflammatory Modulators
Current Pharmaceutical Design Antioxidant Therapy for the Treatment of Oxidative Stress Associated to Cancer and Cancer- Related Anorexia/Cachexia
Current Nutrition & Food Science Preface [Hot Topic: Monoamine Oxidase (MAO) Research (Guest Editor: K. Magyar)]
Current Medicinal Chemistry